Furthermore, aberrant expression of NETO2 has been observed in other types of carcinomas including pancreatic cancer, glioma, nasopharyngeal carcinoma, renal clear cell carcinoma, colorectal cancer and lung adenocarcinoma and represents not only a novel prognostic indicator but also a potential therapeutic target. Here, NETO2 is linked to nasopharyngeal carcinoma.